How to get menopause care as a woman over 40: what works and how to start in 2026

If you are a woman over 40 trying to figure out how to actually get menopause care, the process is more straightforward than the marketing makes it look, and the honest version is different from the version the ads sell. The short answer is that a licensed provider can offer several genuinely effective, evidence-backed options for midlife, but the way in is to start from your goal, sleep, hot flashes, weight, mood, libido, and let a clinician match it to what is proven for you. This page walks through what a provider can prescribe, what each option is used for and what the evidence shows, where the heavily advertised research peptides fit, and what a real consult looks like from the inside.

Can a woman over 40 actually get menopause care prescribed online?

Yes, a licensed provider can prescribe legitimate menopause care after a real evaluation, and much of it can be handled by telehealth. The core therapies for this audience, menopausal hormone therapy, FDA-approved branded GLP-1 medication for weight, and on-label bremelanotide (Vyleesi), are not controlled substances, so the federal in-person-exam rule that gates controlled drugs does not apply to them. What still applies is that the prescriber must hold a full license in the state where you are located, or use a recognized cross-state pathway such as the Interstate Medical Licensure Compact, and your state’s medical board sets its own standards on top of that (HHS Telehealth: licensing across state lines).

What no legitimate provider can do is promise you a prescription before evaluating you. Candidacy is a clinical decision, not a purchase, and that distinction is the single clearest signal of whether a program is worth your time.

What a licensed provider can offer for menopause

Three well-supported options have real evidence for women in midlife, and each is decided on a candidacy basis rather than sold off a menu. Knowing what each one is for saves you from the most common trap: paying for something that has no evidence for the problem you actually have.

Menopausal hormone therapy (HRT) is the established, approved treatment for the core symptoms of menopause. It is the most effective therapy for vasomotor symptoms such as hot flashes and night sweats, and for the genitourinary syndrome of menopause, and it helps prevent bone loss and fracture. For most healthy women who are under 60 or within 10 years of menopause onset, the benefits generally outweigh the risks, with treatment individualized and periodically reassessed (The Menopause Society 2022 hormone therapy position statement). A provider decides candidacy from your symptoms, history, and risk factors. For how HRT stacks up against other options, see peptides versus HRT for menopause.

Branded GLP-1 medication is the best-supported tool for the weight and body-composition side of menopause. The two medicines approved by the FDA for chronic weight management are semaglutide, sold as Wegovy, and tirzepatide, sold as Zepbound (Wegovy prescribing information, DailyMed; Zepbound prescribing information, DailyMed). A responsible program leads with the approved medication and confirms candidacy against the label criteria after reviewing your history and, where indicated, labs. It is worth knowing what changed with compounded versions: the FDA determined the tirzepatide shortage resolved in October 2024 and the semaglutide shortage in February 2025, and the temporary windows that let pharmacies compound them broadly closed in spring 2025, so a cut-price compounded shot marketed as the same medicine as the brand is exactly what recent enforcement has targeted (FDA compounder policy; FDA warning letters to 30 telehealth companies). For the deeper walkthrough, see GLP-1 for menopause weight gain and the broader metabolic and hormone care guide.

On-label bremelanotide (Vyleesi, also called PT-141) is approved by the FDA for one specific use: acquired, generalized hypoactive sexual desire disorder in premenopausal women (Vyleesi prescribing information, FDA). The word premenopausal is decisive here. The approval does not cover postmenopausal women, so use after menopause is off-label, a decision a licensed provider is responsible for evaluating and explaining rather than a settled, approved treatment. Low desire in midlife is common and worth raising, but it has many contributors, and PT-141 is one narrow item on a longer list a clinician should work through. See PT-141 for women for what the label does and does not say.

Where the research peptides marketed to you fit

The peptides most heavily advertised to women over 40 are early-stage science for menopause, not established treatments. Research compounds such as DSIP, marketed for sleep, and MOTS-C, marketed for metabolism, are studied mostly in animal and small early studies, and neither has been tested in a trial of menopausal women; our guides to peptides for sleep during menopause and whether peptides help with menopause symptoms walk through what that research does and does not show. GHK-Cu, the copper peptide, is most familiar to this audience from over-the-counter skincare, where it may be a reasonable ingredient in a routine; it is not a metabolic or hormonal treatment. If one of these is what caught your eye, the useful move is to name the underlying goal, sleep, energy, or metabolic change, and let a provider weigh it against options with stronger evidence.

Status: MOTS-C: Not FDA-approved; sold by some telehealth providers as a compounded prescription. An FDA advisory committee reportedly voted in July 2026 to recommend allowing pharmacies to compound it; nothing has changed yet. DSIP: Not FDA-approved for any use. What these status terms mean.

Start with your goal, not a drug name

The most reliable way to get good menopause care is to bring the problem you want solved rather than the product you saw advertised. A drug name walks you toward whatever a marketer wants to sell; a goal lets a clinician map you to the option with the best evidence for it. In practice that means naming what is actually bothering you.

• Hot flashes, night sweats, sleep disruption, vaginal symptoms, or bone concerns point toward a hormone-therapy conversation, the most effective treatment for those symptoms.
• Weight gain and the shift toward belly fat point toward a candidacy review for a GLP-1 approved by the FDA, alongside protein-forward nutrition and resistance training to protect muscle.
• Low sexual desire is worth raising directly, with the understanding that it has many contributors and that PT-141’s approval is premenopausal-only.
• Thinning scalp hair is a recognized menopausal change worth naming at the same visit (Zouboulis et al., Climacteric 2022); our guide to oral minoxidil for women covers what the trials in women found and the facial hair trade-off.
• Energy, mood, and general “not feeling like myself” deserve a real workup rather than a trending peptide, because those symptoms overlap with thyroid, iron, sleep, and mood issues a provider can actually test for.

A goal-based consult is designed around exactly this: you describe what you want to change, and the clinician tells you what is appropriate and proven for you, including when the honest answer is a therapy you had not heard of, or none at all.

What a legitimate menopause consult actually looks like

A trustworthy consult starts with a real clinical evaluation and never with a checkout page. Expect a provider to review your full medical and medication history, your menopause symptoms and where you are in the transition, and your risk factors, and to order baseline labs where indicated. If a medication is appropriate, a good program starts conservatively, a GLP-1 is titrated up slowly to limit side effects, and schedules follow-up to manage tolerability and reassess. Hormone therapy is chosen for symptom relief and bone protection and is periodically reviewed, not set and forgotten.

Two logistics make this easier than many women expect. Because the core menopause therapies here are not controlled substances, telehealth can handle much of the process as long as the provider is licensed in your state. And because midlife accelerates the loss of muscle, protecting lean mass through adequate protein and resistance training belongs in the plan from the first visit, not as an afterthought.

How to tell a legitimate program from a bad one

The clearest warning sign is any program that promises a prescription before it evaluates you. A few concrete red flags separate honest care from marketing dressed up as medicine:

• A promised prescription, or a flat monthly price for a drug before any clinical review. Candidacy is decided by a clinician after evaluating you, full stop.
• A compounded GLP-1 sold as if it were the same medicine as Wegovy or Zepbound. Compounded semaglutide and tirzepatide are not approved by the FDA, and marketing them as copies of an approved drug is exactly what recent FDA enforcement targeted.
• A research peptide pitched as a menopause treatment. None has been tested in a menopause trial, so a program that leads with one for hot flashes, sleep, or “anti-aging” is selling ahead of the evidence.
• Questionnaire-only intake for anything complex, with no route to speak to a provider. A real program gives you access to a licensed clinician who can evaluate and follow up.

A legitimate program is comfortable telling you no, or telling you the best option is something other than what you came in asking for. That willingness is the feature, not a bug.

The bottom line for starting menopause care over 40

Getting menopause care as a woman over 40 comes down to bringing your goal to a licensed provider and letting the evidence do the sorting. HRT for menopause symptoms, branded GLP-1 for weight, and on-label PT-141 within its premenopausal indication are the therapies with the strongest evidence, each decided on candidacy after a real evaluation, never guaranteed in advance. The research peptides marketed to this audience are still early-stage science for menopause, so a trustworthy program starts from your goal rather than a product. The next step is a real evaluation with a clinician who tells you what is appropriate for you.

Clinical guidance changes. This page reflects the evidence as of October 12, 2026 and is updated when the guidelines, drug labels, or underlying research change.